Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-02T19:40:55.520Z.
Consensus retrieved: 2026-10-02T16:42:09.804Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-02T19:40:55.520Z.
Quote observation: 2026-10-02T19:40:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a42e17afc1a1b5c0c05c4bcc318afc1e85bdb01f5d7a677422ba224d703768eb
Forward PE Ratio (N/A) = Dated Quote Price ($4.08) / Consensus Forward EPS ($-0.90)
FORWARD PE RATIO
N/A
Recursion Pharmaceuticals, Inc.
Market Cap
$2.14B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.14B | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.51B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 5.65 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 54.04 |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | N/A |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | 100.61 |
| NRC Health (NRC)vs › | $459.30M | 23.16 |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.08, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.90 | $-0.95 – $-0.88 | 5 | n/m |
| 2027-12-31 | $-0.90 | $-0.92 – $-0.86 | 5 | n/m |
| 2028-12-31 | $-0.78 | $-1.83 – $-0.21 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
